1 hour ago
HomeMarket NewsStocks NewsAjanta Pharma Q4 net profit rises 18% despite ₹42 crore forex loss; revenue grows 21%
Shares of Ajanta Pharma Ltd ended at ₹2,910.00, up by ₹5.85, or 0.20%, on the BSE.
2 Min Read
Drug firm Ajanta Pharma Ltd on Tuesday (May 5) reported an 18.4% year-on-year rise in net profit for the fourth quarter, with profit at ₹266.7 crore compared with ₹225.3 crore in the year-ago period. PAT margin stood at 19%.
Revenue for the quarter rose 21.5% to ₹1,421.6 crore from ₹1,170.4 crore a year earlier.
EBITDA increased 12.2% to ₹333.4 crore in the March quarter, against ₹297.2 crore in the corresponding period last year. EBITDA margin stood at 23.5% for the quarter, compared with 25.4% in the same period last year.
Also Read: Ajanta Pharma's Paithan plant gets five observations from USFDA; stock volatile
The company reported a mark-to-market forex loss of ₹42 crore during the quarter. Excluding this impact, EBITDA stood at ₹375 crore, up 26% year-on-year, with an EBITDA margin of 26%.
FY26
For FY26, revenue from operations rose 17% to ₹5,453 crore from ₹4,648 crore in FY25. Full-year EBITDA increased 11% to ₹1,395 crore from ₹1,260 crore, with EBITDA margin at 26%.
The company reported a mark-to-market forex loss of ₹103 crore for the year. Excluding this impact, EBITDA stood at ₹1,498 crore, up 18% year-on-year, with EBITDA margin at 27%.
Also Read: Ajanta Pharma shares gain 5% after in-licensing agreement with Biocon for Semgalutide
Profit after tax for FY26 rose 15% to ₹1,056 crore from ₹920 crore in FY25, while PAT margin stood at 19%. Ajanta Pharma said return on capital employed stood at 33% and return on net worth came in at 25% for FY26.
On the regulatory front, the company filed five ANDAs during FY26 and received approvals for four. It launched four products during the year, taking the total number of commercialised ANDAs to 49. As of the end of FY26, 19 ANDAs were awaiting approval from the US FDA, including six with tentative approval.
Research and development expense for the fourth quarter rose to ₹70 crore from ₹53 crore a year earlier, while full-year R&D spending increased to ₹252 crore from ₹161 crore. R&D spend stood at 5% of revenue in both Q4 and FY26.
Shares of Ajanta Pharma Ltd ended at ₹2,910.00, up by ₹5.85, or 0.20%, on the BSE.
(Edited by : Jomy Jos Pullokaran)
